| Document |
Document Title |
|
WO/2008/109577A1 |
Disclosed herein are novel polymorphs of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin
-11-yl)amino]heptanoic acid S,S-dioxide. Also described herein are novel pharmaceutical compositions comprising one or more 7-[(3-chlor...
|
|
WO/2008/102908A1 |
Disclosed is a novel herbicide. Specifically disclosed is a haloalkylsulfonanilide derivative represented by the general formula (1) below, or an agrochemically acceptable salt thereof. (In the formula, Q represents -N(R5)SO2R6, wherein ...
|
|
WO/2008/028958A1 |
The invention relates to novel heterocyclic compounds of the formula ( I ), in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
|
|
WO/2008/012524A1 |
The present invention relates to novel analine derivatives and their use in therapy, in particular their use in the treatment of fungal infections.
|
|
WO/2008/003270A1 |
A method for the preparation of salts of 2-[2-(4-dibenzo[b,fj[l,4]thiazepin-11-yl-1- piperazinyl)ethoxy]ethanol (quetiapine) from the quetiapine base and the respective acid, wherein the salt is precipitated from a mixture of solvents, t...
|
|
WO/2007/117180A1 |
The invention relates to novel azaheterocycles of interest as potential physiologically active substances (agonists, antagonists, receptor modulators, ferment inhibitors, oncolytics, antibacterial and antiparasitic agent etc.), to combin...
|
|
WO/2007/111026A1 |
This invention provides an optical film comprising one layer provided on a light transparent substrate and can satisfy a good balance among an anti-dazzling function, an enhanced contrast, color reproduction, and anti-glare prevention. T...
|
|
WO/2007/104933A1 |
The invention provides a new method for treating disorders associated with activation of the Notch signal transduction pathway comprising administering an effective amount of a compound of Formula (I), in free form or in a pharmaceutical...
|
|
WO/2007/101347A1 |
Disclosed herein are compounds as resented by Formula (I): wherein R1,R2, R3, R4, n, W, A, and Q are as defined herein. The compounds of formula (I) are useful as antagonists of the IAPs via binding to BIR domain. The compounds are usefu...
|
|
WO/2007/102352A2 |
A dibenzothiazepine compound is suitably prepared by subjecting a 2-amino-2'-carboxy-diphenylsulfide compound to dehydration-condensation reaction in the presence of an acidic catalyst; the 2-amino-2'-carboxy-diphenylsulfide compound is ...
|
|
WO/2007/102074A2 |
Novel Salts of Quetiapine are disclosed. These salts of the formula (II) wherein S represents an acid selected from the group consisting of benzoic acid, tartaric acid, oxalic acid, p-toluene sulfonic acid, naphthalene sulfonic acid, suc...
|
|
WO/2007/050425A2 |
A compound of formula I,wherein A, X, q, R1, R2a, R2b, R2c, R3a, and R3b are defined herein, useful as liver X receptor modulator.
|
|
WO/2007/048870A1 |
ABSTRACT The present invention relates to a process for preparing and purifying crystalline quetiapine hemifumarate, which comprises preparing crystalline quetiapine hemifumarate via a crystalline salt, which is not a salt of fumaric acid.
|
|
WO/2007/049532A1 |
A BACE 1 inhibitor containing, as an active ingredient, any one of a compound represented by the formula (I): (wherein ring A is an optionally substituted carbocyclic group or optionally substituted heterocyclic group; E is lower alkylen...
|
|
WO/2007/047737A1 |
Disclosed herein is a compound of Formula (I). Also disclosed herein is a method of modulating the activity of a cannabinoid receptor using a compound of Formula (I). Furthermore, disclosed herein is a method of treating a disease or con...
|
|
WO/2007/036599A1 |
The present invention relates to a process for preparing crystalline quetiapine hemifumarate, which comprises crystallizing or re-crystallizing quetiapine hemifumarate from a mixture of water and a water soluble alcohol.
|
|
WO/2007/020011A1 |
The present invention relates to new processes for the preparation of thiazepines and of salts thereof. Specifically the present invention provides simple one-pot processes for the preparation of thiazepines. The invention further relate...
|
|
WO2006081347B1 |
The invention relates to a formulation for the treatment of acute manic episodes associated with Bipolar I Disorder comprising an antipsychotic agent selected from the group consisting of: a dibenzothiazepine derivative; lithium; and div...
|
|
WO/2007/009656A2 |
The invention relates to a compound of formula (A) and the physiologically acceptable salts thereof. Said compound is suitable as a hypolipidemic agent, for example.
|
|
WO/2007/009655A1 |
The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidaemic.
|
|
WO/2007/004234A1 |
A process for the preparation of 2-[2-(4-Dibenzo[b,f] [l,4] thiazepin-11-yl-1- Ďiperazinyl)ethoxy] ethanol fumarate commonly known as Quetiapine hemifumarate. Dibenzo[b,f] [l,4] thiazepin-11-[10H]one is halogenated with a halogenating a...
|
|
WO/2006/135544A1 |
The invention is directed a method for synthesizing l l-(4-[2-(2- hydroxyethoxy)ethyl]-piperazinyl)-dibenzo[b,f] [l,4]thiazepine (quetiapine) and for recovering quetiapine as its fumarate salt in which dibenzo[b,f][l,4]thiazepine- l l(10...
|
|
WO/2006/117700A2 |
The invention comprises a process for preparing quetiapine and/or its salts, including, quetiapine fumarate. The process generally comprises reacting dibenzothiazepinone (dibenzo[bf][l,4]thiazepin-l l(10H)-one) with phosphorous oxychlori...
|
|
WO/2006/113425A1 |
Provided is a novel synthesis of quetiapine, and pharmaceutically acceptable salts thereof, in which an alkali metal halide or siliyl halide is included in the reaction mixture.
|
|
WO/2006/101496A1 |
The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or...
|
|
WO/2006/097449A1 |
New N-hydroxyamides of n-alkyl carboxylic acids omega substituted with suitable tricyclic systems characterised by a central 7-membered ring, having activity as inhibitors of histone deacetylase (HDAC).
|
|
WO/2006/094549A1 |
A process for the preparation of an 11-(4-substituted-1-piperazinyl)dibenzo[b,f][1,4]thiazepine derivative, of general Formula (I), where A is hydrogen or a -(CH2)2-OH group or a -(CH2)2-0-(CH2)2-OH group, or of a salt thereof, comprises...
|
|
WO/2006/085096A1 |
The invention provides compounds of general formulae I - IV or pharmaceutically acceptable salts thereof : Formulas (I), (II), (III), (IV) The invention also provides methods of preparing the compounds, pharmaceutical compositions compri...
|
|
WO/2006/077602A1 |
Disclosed herein is an industrial process for preparation of Quetiapine by the reaction of 11-piperazinyldibenzo[b,f][1,4]-thiazepine or its salt with 2-(2-chloroethoxy)ethanol in presence of an inorganic base in aqueous condition to for...
|
|
WO/2006/074940A2 |
The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 o...
|
|
WO/2006/056771A1 |
The invention relates to new salts of 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethox
y] ethanol derived from phosphoric acid and obtainable in crystalline form, to a process for their preparation and to pharmaceutical compo...
|
|
WO/2006/056696A2 |
2-alcoxy-3,4,5-trihydroxy-alkylamides, the preparation thereof, compositions containing them and use thereof. The invention relates particularly to 2-alcoxy-3,4,5-trihydroxy-alkylamides, the preparation thereof, compositions containing t...
|
|
WO/2006/056772A2 |
The invention relates to new salts of 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethox
y] ethanol with organic acids and obtainable in crystalline form, to a process for the preparation of the new salts and to pharmaceutical ...
|
|
WO/2006/035293A1 |
The present invention relates to novel polymorphic forms of quetiapine hemifumarate, process for their preparation and pharmaceutical compositions thereof.
|
|
WO/2006/027789A1 |
A process for producing 11-[4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyl]dibenzo [b,f][1,4]thiazepine [I] and a pharmaceutically suitable acid addition salt is disclosed. Accordingly, thiosalicylic acid [XVI] is reacted with o-halonitroben...
|
|
WO/2006/020817A1 |
The present invention discloses novel 5-HT receptor binding agents of Formula 3, wherein X is -CH or -N-. Y is selected from the group consisting of -CR10R11, -NR12, -0-, -S-, -SO-, and -SO2-. R1 to R12 are various substituents selected ...
|
|
WO/2006/001619A1 |
Disclosed is a process for the preparation of l l-(4-[2-(2-hydroxyethoxy)ethyl]-l- piperazinyl)-dibenzo[b,f][l,4]thiazepine. In the process, low-priced 2,2'-dithiosalicylic acid as starting material is subjected to bond formation reactio...
|
|
WO2005103041A9 |
The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention ...
|
|
WO/2005/105793A1 |
A drug which can be used as a muscle relaxation accelerator, therapeutic agent for left ventricular diastolic dysfunction, therapeutic agent for angina pectoris, therapeutic agent for acute pulmonary edema, blood ameliorant for microcirc...
|
|
WO/2005/100366A1 |
Disclosed are proline-rapamycin 42-ester with 2,2-bis(hydroxymethyl)propionic acid (proline-CCI-779) as well as a method for the regiospecific preparation of a rapamycin 42-ester or proline-rapamycin 42-ester with 2,2-bis(hydroxymethyl)p...
|
|
WO/2005/095338A1 |
The invention aims at providing novel compounds having regulatory effect on the activity of GPR (G protein-coupled receptor) 40 and being useful as insulin secretagogue or preventive or therapeutic agent for diabetes and so on. Compounds...
|
|
WO/2005/082873A2 |
The invention relates to novel compounds of 1,4-benzothiazepans and 1,4-benzothiazepins, especially of 5-one compounds, and to the use of the same as medicaments.
|
|
WO/2005/082874A1 |
It is intended to provide a drug useful as a remedy and a preventive for hyperlipemia; a drug also useful as a remedy and a preventive for liver disorders accompanying bile stasis, in particular, primary biliary cirrhosis, primary sclero...
|
|
WO/2005/080976A1 |
A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor dysfunction as an animal model of schizophrenia and with the use of reference memory problems, wherein ...
|
|
WO/2005/066146A1 |
The invention relates to novel methods of preparing a thiazolo[3,4,5-de][4,1]benzothiazepine-type compound and, in particular, methanesulfonate of 6,6-dioxide of 2-imino-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-d
e][4,1]benzoth...
|
|
WO/2005/049585A1 |
The present invention relates to novel macrocyclic compounds of the formula (I) wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or...
|
|
WO/2005/028459A1 |
The present invention discloses a process for the preparation of quetiapine, which comprises the ring closure and deprotection of a compound of the formula (I), as well as novel intermediates in the process.
|
|
WO/2005/028458A1 |
The present invention discloses a process for the preparation of quetiapine, which comprises the ring closure of a compound of the formula shown below, as well as novel intermediates in the process.
|
|
WO/2005/028457A1 |
The present invention discloses a process for the preparation of quetiapine, which comprises the reaction of dibenzo[b,f][1,4]thiazepin-11-ylamine with a compound of the general formula (II) as well as novel intermediates in the process.
|
|
WO/2005/014590A2 |
The invention relates to a procedure for preparing quetiapine by reaction between a compound of formula (II) and a compound of formula (III), in which X means a leaving group and P a protective group of alcohols resistant to alkaline con...
|
